Your session is about to expire
← Back to Search
SPOT Trial Summary
This trial will test if a new method of electrical stimulation can help people with low vision see better. The treatment is relevant to public health because it has the potential to improve the lives of millions of people suffering from low vision.
- Central Vision Loss
- Age-Related Macular Degeneration
SPOT Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
SPOT Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
SPOT Trial Design
Find a Location
Who is running the clinical trial?
- You can't sit still for a long time during eye tracking.You cannot see your own iris with a video eye tracker.You have very poor vision in both eyes (20/100 or worse).You have large blind spots in both of your eyes.You have been diagnosed with macular degeneration.You have a specific type of light sensitivity in the central part of your retina that is worse than in the outer areas, as shown by a special eye test.Your medical records show that you have had this severe level of disease for at least 2 years.You have a specific type of light sensitivity in the center of your retina that is worse than in other parts of your eye, as shown by a special eye test.You have been diagnosed with macular degeneration.You have very poor vision in both eyes (20/100 or worse).Your medical records show that your condition has been severe for at least 2 years.
- Group 1: Condition 1 - 'Scotoma awareness' Training
- Group 2: Condition 2 - Control Training
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the size of the cohort currently participating in this clinical trial?
"Affirmative. Clinicaltrials.gov illustrates that the clinical trial began on November 1st and has recently been updated, with an aim to recruit 16 individuals from one site."
Who is able to be a participant in this clinical trial?
"This research is targeting 16 individuals with macular degeneration aged between 18 and 89. To qualify, applicants must have severely diminished sight in both eyes (20/100 or worse), be officially diagnosed with Macular Degeneration, demonstrably heightened light sensitivity in the macula compared to other regions of their retina as measured by a scanning laser ophthalmoscope (SLO MAIA), and medical documentation verifying that these symptoms have persisted for at least two years."
Are opportunities for patients to participate in this trial still available?
"Affirmative. According to the data available on clinicaltrials.gov, this medical trial has been actively searching for participants since November 1st 2022 and is currently in need of 16 individuals at a single research centre."
What are the primary goals of this research endeavor?
"This trial seeks to evaluate the efficacy of this treatment via assessment of Fixation Stability, Latency of Target Acquisition, Saccadic Precision, and Percentage of Trials that are Useful from Baseline to 6 weeks post-training completion and 14 weeks post-training completion. Secondary outcomes include examining changes in Latency of Target Acquisition (time until target is visible outside scotoma), Saccadic Precision (dispersion when placing targets outside scotoma) and Percentage of Trials that are useful (% dots relative to total trials)."
Does this research accept individuals aged 75 or above?
"To join the clinical trial, individuals must be aged 18 to 89. Additionally, there are 30 trials for minors and 187 specially designed for people over 65 years of age."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends